CPT code 88360 – Tumor Immunohistochemistry

Key takeaways

CPT Code 88360 covers manual quantitative or semiquantitative morphometric analysis of tumor IHC, billed per antibody tested.

Computer-assisted counting of the same stain is reported under CPT 88361, not under 88360.

The report must name the manual method used, such as an H-score, an Allred score, or a counted percentage.

CPT 88360 and 88342 cannot be billed together for the same antibody on the same specimen.

Medicare coverage is LCD-dependent by jurisdiction, and medical necessity has to be documented for each oncology diagnosis.

CPT Code 88360: Official descriptor and clinical definition

The American Medical Association (AMA) publishes the official descriptor for CPT Code 88360. It reads: Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, each antibody; manual. The code sits in the Surgical Pathology section of the CPT codebook, under the Morphometric Analysis, Tumor Immunohistochemistry subheading.

Morphometric analysis means the pathologist measures the staining instead of reading it by eye. Quantitative or semiquantitative describes the output, which is either a counted percentage of positive cells or a defined score. An H-score, an Allred score, and a Quick score all qualify. Purely subjective visual grading does not.

The last word in the descriptor carries the most billing weight. “Manual” is what separates 88360 from CPT 88361, the companion code for computer-assisted counting. Where image analysis software produces the number, the service is reported under 88361 regardless of the antibody tested.

“Each antibody” means the code is reported once per antibody analyzed, not once per specimen. A pathology report analyzing Ki-67, HER2, ER, and PR morphometrically generates four units of 88360.

CPT 88360 code details at a glance

The table below summarizes the key billing parameters for CPT Code 88360. For current reimbursement figures, verify against the CMS Physician Fee Schedule lookup tool, as rates are subject to annual adjustment.

CPT 88360 vs CPT 88342: Key differences coders need to know

The choice between 88360 and 88342 is where IHC claims most often go wrong. CPT 88342 covers qualitative immunohistochemistry analysis of a single antibody, where the pathologist reads staining as positive, negative, or weakly positive. CPT Code 88360 requires a manual measurement, so a defined and reproducible scoring method has to appear in the pathology report.

The audit risk here is upcoding: billing 88360 when the pathology report only documents a qualitative interpretation. CGS Medicare and other MACs review IHC claims for this pattern. If the report says “positive” without a numeric result or a scoring system, 88342 is the correct code, whatever the antibody tested.

CPT 88360 vs CPT 88341 and other immunohistochemistry CPT codes

CPT Code 88360 belongs to a family of immunohistochemistry codes that differ by method rather than by antibody. Reading them in that order prevents both unbundling errors and underbilling. The diagram below maps each documented method to the code it earns.

One bundling rule carries most of the risk. CPT 88341 is an add-on code, and it cannot be reported on a specimen where 88360 is billed for the same antibody. The two codes describe different types of analysis, so they are not two billing levels of one service. Verify current National Correct Coding Initiative (NCCI) edits when billing multiple IHC codes on the same date of service.

Documentation requirements for CPT Code 88360

Documentation is where most CPT Code 88360 claims fail. The pathology report has to carry all of the following elements for the code to be defensible under audit.

• Manual methodology stated: The report must name the manual method used. That means an H-score, an Allred score, a Quick score, or a counted percentage of positive cells. “Morphometric analysis performed” alone is insufficient. Where counting was performed by image analysis software, the service is reported as 88361 rather than 88360.
• Antibody name and clone: Each antibody analyzed must be identified by name (e.g., Ki-67, clone MIB-1). The claim is billed per antibody, so each one needs its own line of documentation.
• Numeric or scored result per antibody: Report the percentage of positive cells, the H-score, or the equivalent numeric output. A qualitative descriptor such as “positive” or “strongly positive” does not satisfy the morphometric standard.
• Medical necessity statement: The ordering diagnosis and clinical indication must be documented. For oncology cases the ICD-10-CM diagnosis code drives medical necessity, so it belongs on the claim and in the clinical note.
• Ordering physician signature: A signed pathology report is required. Unsigned reports and unsigned preliminary reports are a frequent audit finding.
• Specimen identification: The tissue block or slide the stain was performed on must be traceable in the report.

A compliant claim starts with the pathology report rather than with the billing system. When the report and the claim agree on methodology, antibody, and result, denial risk drops substantially.

Medicare and payer coverage for CPT 88360

Medicare covers CPT Code 88360 under Medicare Part B when medical necessity is documented for an oncology-related diagnosis. Coverage is not universal, because Local Coverage Determinations (LCDs) vary by Medicare Administrative Contractor (MAC) jurisdiction. CGS Medicare, which administers Jurisdiction 15 (Kentucky and Ohio), and Noridian Healthcare Solutions each publish their own LCD guidance for IHC services. Check the LCD for your jurisdiction before billing.

The CMS list of CPT/HCPCS codes and the Medicare Coverage Database article (Article ID 57611) confirm that 88360 is covered under three conditions. First, the specimen has to be neoplastic tissue requiring biomarker quantification. Second, the quantitative result has to inform treatment planning directly. Third, the documentation has to satisfy the morphometric methodology standard.

Cosmetic, screening-only, and non-malignant diagnoses typically do not meet medical necessity for 88360 under Medicare. Tracking denials by payer and by jurisdiction is worth the effort here. LCD wording is what most often separates a paid 88360 claim from a rejected one.

ICD-10 codes commonly billed with CPT 88360

CPT Code 88360 is almost always billed alongside oncology ICD-10-CM diagnosis codes, because quantitative IHC morphometry is a cancer biomarker service. The diagnosis code has to support medical necessity for the specific antibody tested.

Payers may deny 88360 claims paired with non-specific or benign diagnosis codes. Always use the most specific ICD-10-CM code available for the confirmed malignancy. Avoid “rule-out” and “suspected” codes. Where pathology is establishing the diagnosis, use the confirmed histologic finding as the primary code.

Modifiers applicable to CPT Code 88360

The correct modifier depends on how the technical and professional components of the analysis are split between the performing laboratory and the interpreting pathologist. Verify modifier applicability against current MAC guidance, since some MACs restrict modifier 91 on laboratory codes.

Where a hospital-based pathology department performs both the staining and the interpretation under a global billing arrangement, no modifier is needed. Use modifier 26 or TC only when the technical and professional components are genuinely split between different billing entities.

Common billing errors and audit triggers for CPT 88360

The Office of Inspector General (OIG) includes IHC billing in its annual work plan, which keeps CPT Code 88360 a consistent audit target. The errors below account for the majority of denials and compliance findings.

• Upcoding 88342 to 88360: Billing CPT 88360 when the pathology report documents only a qualitative visual interpretation. This is the most frequently cited IHC audit finding. The remedy is pathologist education, since morphometric methodology has to be performed rather than assumed.
• Reporting 88360 for a computer-assisted count: The descriptor ends in “manual”, so image analysis software producing the number moves the service to 88361. Payers that price the two codes differently will treat the mismatch as an overpayment.
• Missing methodology documentation: The report states a numeric result such as Ki-67 30% but never identifies the scoring method. Some payers require explicit notation of the validated scoring tool, while others accept a numeric result alone. Check your major payer policies.
• Unbundling errors: Billing both 88342 and 88360 for the same antibody on the same specimen. These are mutually exclusive for the same analyte. NCCI edits catch most of them, but complex IHC panels still warrant manual review.
• Per-specimen billing instead of per-antibody: CPT 88360 is a per-antibody code. Billing one unit for an entire IHC panel of four morphometrically analyzed antibodies underbills the service and leaves legitimate revenue uncollected.
• Non-specific diagnosis codes: Pairing 88360 with a benign or non-specific ICD-10 code that does not support medical necessity for quantitative biomarker analysis. The diagnosis has to reflect an established malignancy with a clear clinical rationale.

For practices with recurring 88360 rejections, denial management workflows are worth building. Tracking IHC denials by code, payer, and reason surfaces systemic documentation problems faster than case-by-case appeals.

How claims management software reduces 88360 denials

Most IHC billing references stop at the code definition. The part that decides whether an 88360 claim is paid sits further downstream. It comes down to how quickly the billing team sees what the payer sent back, and why.

In a typical practice, the pathology report lives in one system, the claim is keyed into another, and the remittance arrives in a third. Nobody sees the pattern until a quarter’s worth of 88360 denials has stacked up. Pabau, an all-in-one practice management system, keeps those three records together on the patient’s file.

Pabau’s cleaner claims management submits claims electronically through our Claim.MD integration and tracks each one through to remittance. The biller can see which 88360 claims were paid, which were downcoded, and which payer sent them back, without exporting anything to a spreadsheet.

The coding decision itself stays with the pathologist and the billing team. What the software changes is the feedback loop. The practice learns that its 88360 documentation is falling short while it can still fix the reports, not after a MAC review.

See every claim through to remittance

Pabau submits claims electronically through our Claim.MD integration and tracks each one back to the patient record. Downcoded 88360 claims surface while the documentation can still be corrected.

Book a demo

Conclusion

CPT Code 88360 pays more than 88342 because it describes more work, and the claim only holds up where the report shows that work. Read the descriptor as an instruction to the pathologist rather than as a billing label. Name the manual method, give the number per antibody, and pair the claim with a specific oncology diagnosis.

The one distinction worth carrying away is the last word of the descriptor. A counted score is 88360, a software-generated count is 88361, and a visual read is 88342. Practices that get this wrong rarely do so once. A monthly reconciliation of claims against reports is worth more than any single appeal.

Book a demo to see how Pabau submits and tracks IHC claims alongside the patient record they came from.

Continue your research

Need guidance on submitting clean IHC claims electronically? Medical claims clearinghouse guide covers how clearinghouse validation catches code-level errors before claims reach payers.

Want to understand how denial codes map to 88360 rejection reasons? Denial codes in medical billing explains the CARC and RARC codes most commonly returned on IHC claim denials.

Exploring how to structure a compliant billing process? Revenue cycle management fundamentals covers how to build a workflow where documentation, coding, and claim submission stay aligned.

Building a superbill that supports the codes you report? How to build a compliant superbill walks through the fields a payer expects to see on every line.

Frequently asked questions